Medicines Articles
The U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response (ASPR) has awarded approximately $12 million to BioCryst Pharmaceuticals for the advanced development of a promising experimental drug for Ebola.
Novo Nordisk has launched Novoeight (antihemophilic factor [recombinant]) in the U.S. for people living with hemophilia A.
A new experimental drug could boost the immune system in older adults by as much as 20 percent, as well as help them to delay other aging effects.
Octapharma USA has launched the Octapharma Co-Pay AssistanceProgram available to von Willebrand’s disease patients who are currently receiving Wilate (von Willebrand factor/coagulation factor VIII complex[human]) or have a prescription to begin therapy.
